Personalised risk-directed clot prevention for patients with cancer

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/1196211

Funding Status
Status not available

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

Blood clots are a leading cause of death among cancer patients, second only to cancer itself. This EL1 program includes clinical and laboratory studies to assess the impact of personalised clot prevention for patients receiving cancer treatments in ambulatory care settings. Laboratory studies and evaluation of outcomes among ‘real-world’ patients with cancers at high risk of developing blood clots, will improve understanding of both clots and cancer, to advance research and clinical practice.

Funded Activity Details

Start Date: 01-01-2020

End Date: End date not available

Funding Scheme: Investigator Grants

Funding Amount: $645,205.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

lung cancer | preventive medicine | risk prediction | thromboembolic disease

Related Links